Adstiladrin
What Adstiladrin is used for
Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Advanced therapy: a gene, cell or tissue-engineered medicine.
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Adstiladrin
- Active substance
- nadofaragene firadenovec
- Disease area
- Non-Muscle Invasive Bladder Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XL10
- Marketing authorisation holder
- Ferring Pharmaceuticals A/S
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Adstiladrin
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Adstiladrin used for?
Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
What is the active substance in Adstiladrin?
Adstiladrin contains nadofaragene firadenovec.
Who makes Adstiladrin?
The EU marketing authorisation holder is Ferring Pharmaceuticals A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU